“For three decades, the 340B drug pricing program has helped hospitals that serve high numbers of low-income patients offer and expand a range of important programs and services that advance health within their communities,” writes AHA President and CEO Rick Pollack in the Congress Blog at The Hill. READ MORE

Related News Articles

Headline
The AHA today released a new report showing how the unlawful actions of drug companies to limit 340B pricing with community and specialty pharmacies are…
Headline
AHA today urged the U.S. District Court for the District of Columbia to order the Department of Health and Human Services to promptly repay 340B hospitals…
Headline
The Centers for Medicare & Medicaid Services late today posted a final rule on its website that will increase Medicare hospital outpatient prospective…
Headline
As a result of AHA’s successful litigation to stop the Centers for Medicare & Medicaid Services’ unlawful 340B payment policy in calendar year 2022,…
Headline
The Department of Health and Human Services will begin restoring a payment rate of average sales price plus 6% for 340B drug claims in about two weeks, the…
Headline
The United States District Court for the District of Columbia today ruled in favor of the AHA, holding that the Department of Health and Human Services…